Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegenerative Disease and Oncology Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RNF19A drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RNF19A (Dorfin) Recombinant Protein / Ring Domain Mutants High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View RNF19A Products |
| Gene Delivery | RNF19A Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View RNF19A Products |
| Benchmark Ab | Anti-RNF19A Recombinant Antibody Recombinant positive control for Western Blot, IHC, and IP. |
View RNF19A Products |
| Validator | RNF19A siRNA Set For knockdown verification and functional validation in cell-based assays. |
View RNF19A Products |
| Related Target A | SOD1 (Superoxide Dismutase 1) Substrate of RNF19A; critical mutant forms (e.g., G93A) for ALS research. |
View SOD1 Products |
| Related Target B | SNCA (Alpha-Synuclein) Associated pathway target; RNF19A ubiquitinates synphilin-1, interacting with SNCA in Parkinson's disease. |
View SNCA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| E3 Ligase Activity Verification | Sequence-verified, biologically active domains with high purity (>95%) to support in vitro ubiquitination assays. |
| Subfamily Off-Target Screening | Selectivity panels including RNF19B and other RNF family proteins strictly verified by mass spectrometry. |
| Lack of Controls | Clinical-grade benchmark antibodies and inactive RING-domain mutants (e.g., C318S) available as negative controls. |
| False Positives in Knockdown | Sequence-verified siRNA pool designed for highly specific gene silencing with minimal off-target effects. |
Live RNF19A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RNF19A therapeutics is intensifying, with major players shifting focus from traditional small-molecule inhibitors to targeted protein degradation (PROTACs) and molecular glues. As first-generation therapies targeting neurodegenerative pathways reach the clinic, the next wave of R&D is targeting RNF19A's oncogenic roles in glioblastoma and breast cancer, leveraging its E3 ligase activity to selectively degrade disease-driving proteins.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC / Molecular Glue | Arvinas, Kymera Therapeutics | Neurodegenerative Diseases (ALS, PD), Oncology | Ternary Complex Formation (Need high-purity recombinant RNF19A & substrates) |
| Small Molecule Inhibitors | Academic Consortia, Biotech Startups | Glioblastoma, Solid Tumors | Enzymatic Ubiquitination Assay (Need functional wild-type and mutant RNF19A) |
| Gene Therapy (RNAi/AAV) | Alnylam, Voyager Therapeutics | Amyotrophic Lateral Sclerosis (ALS) | In vitro Knockdown Validation (Need sequence-verified siRNA and Lentivirus) |